Fibrates: What Have We Learned in the Past 40 Years?

James M. Backes, Pharm.D.; Cheryl A. Gibson, Ph.D.; Janelle F. Ruisinger, Pharm.D.; Patrick M. Moriarty, M.D.


Pharmacotherapy. 2007;27(3):412-424. 

In This Article

Evidence for Combination Therapy

Use of fibrates together with statins is becoming a more common practice, yet studies evaluating clinical event reduction with this combination are lacking. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, sponsored by the National Institutes of Health, will evaluate clinical outcomes with use of a statin (simvastatin) and fibrate (fenofibrate).[73] Patients with a previous history of type 2 diabetes will be randomly assigned to receive statin monotherapy or the combination of a statin and fibrate. The ACCORD trial, to be completed in 2009, should provide valuable long-term safety information on combination therapy and help determine whether the addition of a fibrate to statin therapy provides further reduction in clinical events. Moreover, presentation of this trial is coming at a very important time, as rapidly growing populations with mixed dyslipidemia (i.e., type 2 diabetes, metabolic syndrome) are expected to double worldwide by 2030.[74]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: